Travoprost ophthalmic- Ocular Therapeutix

Drug Profile

Travoprost ophthalmic- Ocular Therapeutix

Alternative Names: OTX TIC; OTX-TP; OTX-TP1; OTX-TP2; OTX-TPa; OTX-TPb; Sustained release travoprost

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ocular Therapeutix
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 07 Nov 2017 Ocular Therapeutics plans a second phase I trial for Glaucoma in USA in the first half of 2018
  • 07 Nov 2017 Ocular Therapeutix announces intention to submit IND to US FDA for Glaucoma in the first quarter of 2018
  • 07 Nov 2017 Ocular Therapeutics plans a second phase III trial for Glaucoma and Ocular hypertension in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top